Considering inflammatory cytokines and NO as potential mediators of pancreatic beta-cell destruction in diabetes, and since sitagliptin and metformin suppressed iNOS expression in the islet cells, these data point out to the same direction as ours and emphasize the potential benefit of both agents in such condition. The gene discussed is NOS2; the disease is diabetes mellitus.